India’s pharmaceutical patent system differs significantly from those in the United States, Europe, and other developed markets. For international buyers sourcing generic medicines from India, understanding how patents work is essential — it determines when generics become available, how prices evolve, and which products you can legally import. This guide explains India’s patent framework, key legal provisions that enable early generic entry, and what buyers should watch for.
🔬 How Pharmaceutical Patents Work in India
India grants pharmaceutical patents with a standard term of 20 years from the filing date, consistent with World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement obligations. However, India’s Patents Act, 1970 (as amended in 2005) includes several unique provisions that shape how drug patents operate in practice.
Product vs. Process Patents: Before 2005, India only granted process patents for pharmaceuticals — meaning companies could patent the method of making a drug but not the drug molecule itself. This allowed Indian manufacturers to produce the same molecule using different processes, creating India’s early generic industry. After the 2005 amendment to comply with TRIPS, India began granting product patents for new chemical entities filed after 1995.
Key implication for buyers: Drugs invented before 1995 generally have no product patent protection in India and are freely available as generics. Drugs patented after 2005 enjoy the full 20-year term, but India’s unique provisions allow generic entry earlier than in many other countries.
📜 India’s Unique Patent Law Provisions
Several provisions in Indian patent law directly influence when generic versions of patented drugs become available:
Section 3(d) — Preventing Evergreening
India’s Section 3(d) of the Patents Act prevents pharmaceutical companies from obtaining new patents on new forms of known substances (polymorphs, hydrates, isomers, combinations) unless they demonstrate significantly enhanced efficacy. This provision has blocked attempts to extend patent protection through minor modifications, notably in the landmark Novartis v. Union of India case (2013) concerning the cancer drug Glivec (imatinib mesylate).
Buyer impact: Section 3(d) means that many secondary patents that would extend market exclusivity in the US or Europe are rejected in India, allowing generic versions to launch closer to the primary patent expiry.
Pre-Grant Opposition
Indian patent law allows pre-grant opposition — any person can file an opposition to a patent application before it is granted, on grounds including lack of novelty, obviousness, or failure to meet Section 3(d) requirements. This mechanism has been used extensively by Indian generic manufacturers to prevent or narrow pharmaceutical patents before they take effect.
Bolar Exemption
India permits the Bolar exemption, allowing generic manufacturers to develop, test, and obtain regulatory approval for generic versions of patented drugs before the patent expires. This means that on the very day a patent expires, Indian companies can launch their generic versions — unlike markets where regulatory approval must be sought only after patent expiry, creating a lag of months or years.
The Bolar exemption is codified in Section 107A of the Patents Act and has been a critical driver of India’s rapid generic launches following patent expiries [Reference: WIPO Bolar Exemption Overview].
Compulsory Licensing
Under Section 84 of the Patents Act, India can grant compulsory licenses for patented drugs if the patent holder has not made the drug available at a reasonably affordable price or in sufficient quantity to meet public demand. India also grants compulsory licenses for export to countries with insufficient manufacturing capacity under the WTO Doha Declaration on public health.
The most notable example was the 2012 compulsory license granted to Natco Pharma for Bayer’s cancer drug Nexavar (sorafenib tosylate), reducing the price from approximately ₹280,000 to ₹8,800 per month [Reference: Indian Patent Office Records].
⏰ When Do Generic Launches Happen in India?
The timeline from drug invention to generic availability in India generally follows this pattern:
- Years 0-5: Patent application filed, drug undergoes clinical trials overseas. No generic activity allowed during this phase for the patented molecule.
- Years 5-8: Drug launches in developed markets. Indian generic companies begin developing processes using the Bolar exemption.
- Years 8-12: Pre-grant oppositions may be filed. Patent litigation begins. Some secondary patents may be rejected under Section 3(d).
- Years 15-18: Nearing patent expiry. Generic companies file for CDSCO approval (marketing authorization). Manufacturing scale-up begins.
- Year 20 (Patent Expiry): Generic products launch immediately — often on the same day — due to the Bolar exemption.
In practice, many drugs become available as generics in India earlier than in the US or Europe because of successful pre-grant oppositions that narrow or invalidate patent claims, or because the drug was not originally patented in India at all (pre-1995 drugs).
📊 Case Study: Semaglutide Patent Expiry in India (2026)
The ongoing semaglutide patent landscape in India illustrates the system in action. In March 2026, Novo Nordisk’s patent on semaglutide (the active ingredient in Ozempic and Wegovy) expired in India, triggering one of the largest generic launches in Indian pharmaceutical history:
- Over 50 Indian pharmaceutical companies launched branded generic versions of semaglutide immediately after patent expiry [Reference: NDTV, March 2026].
- Monthly treatment costs dropped from approximately ₹5,000-7,000 for the branded product to ₹1,200-2,000 for generic versions — a 70-80% price reduction [Reference: Reuters, March 2026].
- Indian manufacturers such as Sun Pharma, Dr. Reddy’s, Cipla, and Lupin received CDSCO approval weeks before patent expiry, enabled by the Bolar exemption, allowing same-day launch.
- The price drop expanded access to GLP-1 therapy for millions of Indian patients and attracted international buyers seeking affordable semaglutide [Reference: BBC, CNBC, Bloomberg, multiple reports 2026].
This pattern is expected to repeat for other blockbuster drugs approaching patent expiry in India in the coming years.
🛒 What International Buyers Should Know
For international buyers and importers of Indian generic medicines, understanding patent status is critical to making informed purchasing decisions:
- Verify patent status before sourcing: Not all drugs available in India are legally approvable in your country. Check the patent landscape in both India and your destination market.
- Patent expiry ≠ automatic global availability: A generic may be legal to manufacture in India but still patent-protected in your country. Indian law permits manufacture for export, but import regulations vary by jurisdiction.
- Timing matters for pricing: The biggest price drops occur immediately after patent expiry when multiple Indian manufacturers launch simultaneously. Prices tend to stabilize after 12-24 months as competition consolidates.
- Quality remains consistent: Indian generic manufacturers that are WHO-GMP certified and CDSCO-approved follow the same manufacturing standards regardless of whether the product is patented or generic. The price difference reflects competition, not quality.
- Engage reliable suppliers: For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
✅ Conclusion
India’s patent system strikes a unique balance between rewarding pharmaceutical innovation and enabling affordable access to medicines through timely generic competition. The combination of Section 3(d), pre-grant opposition, the Bolar exemption, and compulsory licensing creates a framework where Indian generics consistently reach patients — and international buyers — sooner and at lower cost than in most other countries. By understanding these mechanisms, buyers can better time their sourcing decisions and navigate the regulatory landscape with confidence.
For more information, contact IMSDA at contact@indiamedicine.org.